Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

JERSEY CITY, N.J. -- Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicine Emgality® (galcanezumab) in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. This expanded partnership builds on Organon’s role as sole distributor and promoter of Emgality in Europe since February 2024. Read More

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets